MA54758A - Inhibiteurs de pcsk9 et leurs procédés d'utilisation - Google Patents
Inhibiteurs de pcsk9 et leurs procédés d'utilisationInfo
- Publication number
- MA54758A MA54758A MA054758A MA54758A MA54758A MA 54758 A MA54758 A MA 54758A MA 054758 A MA054758 A MA 054758A MA 54758 A MA54758 A MA 54758A MA 54758 A MA54758 A MA 54758A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- pcsk9 inhibitors
- pcsk9
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962794239P | 2019-01-18 | 2019-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54758A true MA54758A (fr) | 2022-04-27 |
Family
ID=71608564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054758A MA54758A (fr) | 2019-01-18 | 2020-01-16 | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
Country Status (15)
Country | Link |
---|---|
US (2) | US11603523B2 (fr) |
EP (1) | EP3911640A4 (fr) |
JP (1) | JP2022518016A (fr) |
KR (1) | KR20210116549A (fr) |
CN (1) | CN113412258A (fr) |
AU (2) | AU2020209216A1 (fr) |
BR (1) | BR112021013924A2 (fr) |
CA (1) | CA3125767A1 (fr) |
EA (1) | EA202191890A1 (fr) |
IL (1) | IL284661A (fr) |
MA (1) | MA54758A (fr) |
MX (1) | MX2021008661A (fr) |
SG (1) | SG11202107615TA (fr) |
TW (1) | TW202042817A (fr) |
WO (1) | WO2020150474A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11248001B2 (en) * | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
CN113248501B (zh) * | 2021-06-17 | 2021-10-08 | 南京韦尔优众医药有限公司 | Cly系列化合物及其制备方法和制备药物的用途 |
CN113735846A (zh) * | 2021-10-11 | 2021-12-03 | 河北师范大学 | 一种苯并噻唑衍生物及其医药用途 |
TW202333563A (zh) * | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
WO2024062090A1 (fr) | 2022-09-23 | 2024-03-28 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
WO2024062089A1 (fr) | 2022-09-23 | 2024-03-28 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0765313B1 (fr) | 1994-06-17 | 2003-08-20 | F. Hoffmann-La Roche Ag | Derives n,n'-bis(quinolin-4-yle)-diamine, leur preparation et leur utilisation en tant qu'antipaludeens |
WO1996018616A1 (fr) | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | 2-aminopyridines substituees utilisees comme inhibiteurs de synthase d'oxyde d'azote |
SE9603285D0 (sv) | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
US5874438A (en) | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
US20040138284A1 (en) | 2000-02-11 | 2004-07-15 | Matthias Wiesner | Indol-3-yl derivatives |
GB0014022D0 (en) | 2000-06-08 | 2000-08-02 | Novartis Ag | Organic compounds |
US7179912B2 (en) | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
EP1217000A1 (fr) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibiteurs du factor Xa et factor VIIa |
PL204653B1 (pl) | 2001-09-21 | 2010-01-29 | Bristol Myers Squibb Co | Pochodna pirazolo [3, 4-c] pirydyny, jej zastosowanie i kompozycja farmaceutyczna |
WO2003059891A1 (fr) | 2002-01-18 | 2003-07-24 | Pharmacia Corporation | Pyridazinones substituees inhibant la map kinase p38 |
EP1505966A4 (fr) | 2002-05-10 | 2006-08-30 | Bristol Myers Squibb Co | Derives cycloalkyles 1,1-disubstitues utilises en tant qu'inhibiteurs du facteur xa |
JP2005536554A (ja) | 2002-08-23 | 2005-12-02 | ユニバーシティ オブ コネチカット | 新規なビフェニル及びビフェニル様カンナビノイド |
EP1464335A3 (fr) | 2003-03-31 | 2007-05-09 | Taisho Pharmaceutical Co. Ltd. | Derivés de quinolines, tetrahydroquinolines et pyrimidines comme antagonistes du MCH |
UY28282A1 (es) | 2003-04-22 | 2004-11-30 | Avanir Pharmaceuticals | Mediadores peptidicos del trasporte inverso de colesterol para el tratamiento de hipercolesterolemia |
RU2006145961A (ru) * | 2004-06-09 | 2008-07-20 | Аванир Фармасьютикалс (Us) | Гетероциклические производные для лечения гиперлипидемии и связанных заболеваний |
CA2580845A1 (fr) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques |
US20080090863A1 (en) | 2004-09-30 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor |
US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
CA2585490A1 (fr) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases |
GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
CA2603830A1 (fr) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | Pyridine [2,3-b] pyrazinones |
US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
JP2007291087A (ja) | 2006-03-29 | 2007-11-08 | Taisho Pharmaceut Co Ltd | ピリジン誘導体及びその使用に関連する治療法 |
RS52626B (en) | 2006-07-25 | 2013-06-28 | Cephalon Inc. | PYRIDIZINONA DERIVATIVES |
US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
WO2008061796A2 (fr) | 2006-11-24 | 2008-05-29 | Ac Immune Sa | Nouveaux composés destinés au traitement de maladies associés à des protéines amyloïdes ou de type amyloïde |
JP5410295B2 (ja) | 2006-12-13 | 2014-02-05 | ジボダン ネーデルランド サービシーズ ビー.ヴイ. | カルボン酸およびプリン、ピリミジン、ヌクレオシドまたはヌクレオチドのフレーバー調節誘導体 |
WO2009055783A2 (fr) * | 2007-10-26 | 2009-04-30 | Schering Corporation | Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol |
EP2296653B1 (fr) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Composés et procédés de traitement des troubles inflammatoires et fibrotiques |
WO2010048149A2 (fr) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie |
KR20120092567A (ko) | 2009-08-05 | 2012-08-21 | 벌시테크 리미티드 | 항바이러스 화합물 및 이를 제조하는 방법 및 이의 이용 방법 |
WO2011147199A1 (fr) | 2010-05-28 | 2011-12-01 | Versitech Limited | Composés et procédés pour le traitement d'infections virales |
BR112012030787A2 (pt) | 2010-06-04 | 2020-09-01 | Kowa Company Ltd. | derivado opticamente de dibenzilamina para preparar o mesmo |
WO2012009649A1 (fr) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Inhibiteurs mif et leurs utilisations |
WO2012016133A2 (fr) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 |
US8987271B2 (en) | 2010-12-22 | 2015-03-24 | Eutropics Pharmaceuticals, Inc. | 2,2′-biphenazine compounds and methods useful for treating disease |
CN103339110A (zh) | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
CA2837312A1 (fr) | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Modulateurs allosteriques du recepteur 5 du glutamate methabotropique et methodes d'utilisation associees |
JP5741850B2 (ja) | 2011-09-13 | 2015-07-01 | コニカミノルタ株式会社 | 光学フィルム、それを含む偏光板および液晶表示装置 |
WO2013137371A1 (fr) | 2012-03-15 | 2013-09-19 | 興和株式会社 | Nouveau composé pyrimidine et médicament comprenant celui-ci |
KR20150059638A (ko) | 2012-05-25 | 2015-06-01 | 카타베이시스 파마슈티칼즈, 인코포레이티드 | 전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법 |
WO2014012360A1 (fr) | 2012-07-18 | 2014-01-23 | Sunshine Lake Pharma Co., Ltd. | Dérivés hétérocycliques azotés et leur application dans des médicaments |
TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
WO2014117919A1 (fr) | 2013-02-04 | 2014-08-07 | Merck Patent Gmbh | Modulateurs allostériques positifs de mglur3 |
CN107200749B (zh) | 2013-03-12 | 2019-09-03 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
EP2986599A1 (fr) * | 2013-04-17 | 2016-02-24 | Pfizer Inc. | Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires |
WO2014201173A1 (fr) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Composés de sulfonamide bicycliques utilisés en tant qu'inhibiteurs des canaux sodiques |
AR092240A1 (es) | 2013-08-26 | 2015-04-08 | Sunshine Lake Pharma Co Ltd | Derivados heterociclicos nitrogenados y su aplicacion en farmacos |
CN104558685B (zh) | 2013-10-24 | 2017-09-29 | 中国石油化工股份有限公司 | 一种磷氮膨胀型阻燃剂及其合成方法 |
JP2017516858A (ja) | 2014-05-30 | 2017-06-22 | ユニヴェルシテ・パリ・デカルト | Hiv感染症の治療に使用するための1,3ジアミノ官能性を有する環式化合物 |
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
WO2016049524A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
WO2016054388A1 (fr) | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibiteurs de glutaminase |
CA2973873A1 (fr) | 2015-01-20 | 2016-07-28 | Merial, Inc. | Composes anthelmintiques, compositions et leur procede d'utilisation |
WO2017125506A1 (fr) | 2016-01-20 | 2017-07-27 | Janssen Sciences Ireland Uc | Pyrimidines à substitution aryle à utiliser dans une infection par le virus de la grippe |
EP3429591B1 (fr) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation |
TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
WO2018106818A1 (fr) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Procédés de promotion de la prolifération de cellules bêta |
WO2018106820A1 (fr) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Procédés de promotion de la prolifération de cellules bêta |
US11091466B2 (en) | 2017-03-17 | 2021-08-17 | Cardio Therapeutics Pty Ltd | Heterocyclic inhibitors of PCSK9 |
WO2018175746A1 (fr) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing |
KR20200020781A (ko) | 2017-06-14 | 2020-02-26 | 트레베나, 인코포레이티드. | S1p1 활성을 조정하기 위한 화합물 및 그를 사용하는 방법 |
CN109384712B (zh) | 2017-08-14 | 2021-05-07 | 北京宽厚医药科技有限公司 | 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用 |
EP3676268A1 (fr) | 2017-10-20 | 2020-07-08 | Dana-Farber Cancer Institute, Inc. | Composés hétérobifonctionnels présentant une spécificité améliorée pour le bromodomaine de brd4 |
UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
WO2019111225A1 (fr) | 2017-12-08 | 2019-06-13 | Avaliv Therapeutics | Composés et procédés destinés au traitement de la stéatohépatite non alcoolique |
KR20200109358A (ko) | 2018-01-17 | 2020-09-22 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제 |
CA3097774A1 (fr) | 2018-04-24 | 2019-10-31 | Vertex Pharmaceuticals Incorporated | Composes de pteridinone et leurs utilisations |
US20190374526A1 (en) | 2018-06-06 | 2019-12-12 | Merck Sharp & Dohme Corp. | Substituted Heterocyclic Compounds as Inhibitors of PRDM9 |
US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
-
2020
- 2020-01-16 BR BR112021013924-9A patent/BR112021013924A2/pt unknown
- 2020-01-16 AU AU2020209216A patent/AU2020209216A1/en not_active Abandoned
- 2020-01-16 SG SG11202107615TA patent/SG11202107615TA/en unknown
- 2020-01-16 MA MA054758A patent/MA54758A/fr unknown
- 2020-01-16 EA EA202191890A patent/EA202191890A1/ru unknown
- 2020-01-16 CN CN202080009277.4A patent/CN113412258A/zh active Pending
- 2020-01-16 MX MX2021008661A patent/MX2021008661A/es unknown
- 2020-01-16 CA CA3125767A patent/CA3125767A1/fr active Pending
- 2020-01-16 KR KR1020217025811A patent/KR20210116549A/ko unknown
- 2020-01-16 WO PCT/US2020/013882 patent/WO2020150474A1/fr unknown
- 2020-01-16 JP JP2021541180A patent/JP2022518016A/ja active Pending
- 2020-01-16 US US16/744,932 patent/US11603523B2/en active Active
- 2020-01-16 EP EP20741354.3A patent/EP3911640A4/fr active Pending
- 2020-01-17 TW TW109101672A patent/TW202042817A/zh unknown
-
2021
- 2021-07-06 IL IL284661A patent/IL284661A/en unknown
-
2023
- 2023-01-25 US US18/159,270 patent/US20230407285A1/en active Pending
- 2023-03-31 AU AU2023201972A patent/AU2023201972A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021008661A (es) | 2021-08-19 |
CA3125767A1 (fr) | 2020-07-23 |
TW202042817A (zh) | 2020-12-01 |
AU2020209216A1 (en) | 2021-08-26 |
EA202191890A1 (ru) | 2022-02-03 |
KR20210116549A (ko) | 2021-09-27 |
SG11202107615TA (en) | 2021-08-30 |
EP3911640A1 (fr) | 2021-11-24 |
JP2022518016A (ja) | 2022-03-11 |
CN113412258A (zh) | 2021-09-17 |
WO2020150474A1 (fr) | 2020-07-23 |
US20230407285A1 (en) | 2023-12-21 |
BR112021013924A2 (pt) | 2021-09-21 |
US20200231584A1 (en) | 2020-07-23 |
US11603523B2 (en) | 2023-03-14 |
EP3911640A4 (fr) | 2022-10-26 |
AU2023201972A1 (en) | 2023-05-04 |
IL284661A (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA54261A (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
MA54758A (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
MA55301A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA55885A (fr) | Chélateurs macrocycliques et leurs procédés d'utilisation | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
MA53919A (fr) | Constructions d'acides nucléiques et procédés d'utilisation | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA52797A (fr) | Inhibiteurs de masp -2 et procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA52963A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
MA53235A (fr) | Indoles substitués et procédés d'utilisation associés | |
MA55025A (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation |